Bio Impact Capital LLC Avadel Pharmaceuticals PLC Transaction History
Bio Impact Capital LLC
- $611 Million
- Q1 2024
A detailed history of Bio Impact Capital LLC transactions in Avadel Pharmaceuticals PLC stock. As of the latest transaction made, Bio Impact Capital LLC holds 871,149 shares of AVDL stock, worth $12.7 Million. This represents 2.41% of its overall portfolio holdings.
Number of Shares
871,149
Previous 664,986
31.0%
Holding current value
$12.7 Million
Previous $9.39 Million
56.7%
% of portfolio
2.41%
Previous 2.28%
Shares
6 transactions
Others Institutions Holding AVDL
# of Institutions
132Shares Held
68.4MCall Options Held
1.01MPut Options Held
2.03M-
Janus Henderson Group PLC London, X012.9MShares$188 Million0.12% of portfolio
-
Rtw Investments, LP New York, NY8.8MShares$128 Million2.38% of portfolio
-
Polar Capital Holdings PLC London, X06.75MShares$98.1 Million0.71% of portfolio
-
Gendell Jeffrey L Greenwich, CT5.71MShares$82.9 Million3.76% of portfolio
-
Vivo Capital, LLC Palo Alto, CA3.97MShares$57.7 Million8.97% of portfolio
About AVADEL PHARMACEUTICALS PLC
- Ticker AVDL
- Exchange NASDAQ
- Sector Healthcare
- Industry Drug Manufacturers—Specialty & Generic
- Shares Outstandng 60,581,300
- Market Cap $880M
- Description
- Avadel Pharmaceuticals plc operates as a biopharmaceutical company in the United States. Its lead product candidate is FT218, a formulation of sodium oxybate, which is in a Phase 3 clinical trial for the treatment of excessive daytime sleepiness and cataplexy in adults with narcolepsy. The company was formerly known as Flamel Technologies SA and...